Fingolimod Immune Effects Beyond Its Sequestration Ability

Fingolimod is the first orally administered drug approved for the treatment of relapsing–remitting multiple sclerosis (MS). This drug, modulating sphingosine receptors, regulates the trafficking of lymphocytes between primary and secondary lymphoid organs, trapping naïve T cells and central memory T...

Descripción completa

Detalles Bibliográficos
Autores principales: Sica, Francesco, Centonze, Diego, Buttari, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858921/
https://www.ncbi.nlm.nih.gov/pubmed/31696392
http://dx.doi.org/10.1007/s40120-019-00162-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858921/
https://www.ncbi.nlm.nih.gov/pubmed/31696392
http://dx.doi.org/10.1007/s40120-019-00162-7

Ejemplares similares